List of Victoza drug patents

Victoza is owned by Novo Nordisk Inc.

Victoza contains Liraglutide Recombinant.

Victoza has a total of 14 drug patents out of which 3 drug patents have expired.

Expired drug patents of Victoza are:

  • US8846618
  • US8846618*PED
  • US6268343

Victoza was authorised for market use on 25 January, 2010.

Victoza is available in solution;subcutaneous dosage forms.

Victoza can be used as method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide, a method for improving glycemic control in adults with type 2 diabetes mellitus.

The generics of Victoza are possible to be released after 09 July, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2022

(5 months ago)

US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618 NOVO NORDISK INC Stable formulation of modified GLP-1
Jun, 2022

(7 months ago)

US8846618

(Pediatric)

NOVO NORDISK INC Stable formulation of modified GLP-1
Dec, 2022

(a month ago)

US6268343

(Pediatric)

NOVO NORDISK INC Derivatives of GLP-1 analogs
Feb, 2023

(24 days from now)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(4 months from now)

US8579869

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(10 months from now)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(1 year, 3 months from now)

US7762994

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(1 year, 9 months from now)

US8114833

(Pediatric)

NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(3 years from now)

US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(9 years from now)

US9265893

(Pediatric)

NOVO NORDISK INC Injection button
Mar, 2033

(10 years from now)

US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(13 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jul, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 17, 2022
Pediatric Exclusivity (PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide; A method for improving glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of VICTOZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

List of large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6268343 NA Derivatives of GLP-1 analogs
Aug, 2022

(5 months ago)

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in